Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05515237 · ClinicalTrials.gov registry record · NA

Constraint-Induced Movement Therapy Plus Sensory Components After Stroke

A NA study of Stroke and Upper Extremity Paresis, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT05515237 is a NA study of Stroke and Upper Extremity Paresis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 15 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05515237, a NA study of Stroke and Upper Extremity Paresis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

Constraint-Induced Movement Therapy or CI Therapy is a form of treatment that systematically employs the application of selected behavioral techniques delivered in intensive treatment over consecutive day with the following strategies utilized: behavioral strategies are implemented to improve the use of the more- affected limb in life situation called a Transfer Package (TP), motor training using a technique called shaping to make progress in successive approximations, repetitive, task oriented training, and strategies to encourage or constrain participants to use the more-affected extremity including restraint of the less-affected arm in the upper extremity (UE) protocol. Numerous studies examining the application of CI therapy with UE rehabilitation after stroke have demonstrated strong evidence for improving the amount of use and the quality of the more-affected UE functional use in the participant's daily life situation. CI Therapy studies with adults, to date, have explored intensive treatment for participants with a range from mild-to-severe motor impairment following stroke with noted motor deficits and limited use of the more-affected arm and hand in everyday activities. Each CI Therapy protocol was designed for the level of impairment demonstrated by participants recruited for the study. However, often following stroke, patients not only have motor deficits but somatosensory impairments as well. The somatosensory issues have not, as yet, been systematically measured and trained in CI Therapy protocols with adults and represent an understudied area of stroke recovery. We hypothesize that participants with mild-to-severe motor impairment and UE functional use deficits can benefit from CI therapy protocols that include somatosensory measurement and training components substituted for portions of motor training without loss in outcome measure gains. Further, we hypothesize that adults can improve somatosensory outcomes as a result of a combined CI therapy plus

Interventions

  • BEHAVIORAL Grade 2-5 CI Therapy + Sensory Components

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-03-30
Est. Completion 2026-06
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT05515237

The ClinicalTrials.gov registry entry for NCT05515237 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Grade 2-5 CI Therapy + Sensory Components is the first listed.

NCT05515237 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT05515237 about?

NCT05515237 is a clinical study titled "Constraint-Induced Movement Therapy Plus Sensory Components After Stroke". Constraint-Induced Movement Therapy or CI Therapy is a form of treatment that systematically employs the application of selected behavioral techniques delivered in intensive treatment over consecutive day with the following strategies utilized: behavioral strategies are implemented to improve the us...

What is the current status of trial NCT05515237?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2023-03-30. Estimated completion is 2026-06.

What conditions does trial NCT05515237 study?

This clinical trial studies the following conditions: Stroke, Upper Extremity Paresis, CVA (Cerebrovascular Accident).

What interventions are being tested in trial NCT05515237?

The interventions under investigation include: Grade 2-5 CI Therapy + Sensory Components (BEHAVIORAL).

Who is sponsoring clinical trial NCT05515237?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05515237 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.